Cellebrite DI (CLBT) EBIT Margin (2020 - 2025)

Cellebrite DI's EBIT Margin history runs 6 years deep, the most recent figure standing at 16.15% for Q4 2025.

• On a quarterly basis, EBIT Margin rose 173.0% year-over-year to 16.15% in Q4 2025; TTM through Dec 2025 was 13.98%, a 21.0% decrease from a year earlier, with the FY2025 full-year figure at 13.98%, down 21.0% from the prior year.
• EBIT Margin improved to 16.15% in Q4 2025 per CLBT's latest filing, from 15.07% in the prior quarter.
• Across five years, EBIT Margin topped out at 18.2% in Q3 2024 and bottomed at 10.25% in Q4 2022.
• The 5-year median for EBIT Margin is 10.86% (2025), against an average of 7.48%.
• Across the five-year window, EBIT Margin tumbled 2284 bps in 2022 and surged 2637 bps in 2023, its largest moves.
• Year by year, EBIT Margin stood at 6.34% in 2021, then sank by 262 bps to 10.25% in 2022, then jumped by 257 bps to 16.13% in 2023, then dropped by 11 bps to 14.42% in 2024, then rose by 12 bps to 16.15% in 2025.
• Per Business Quant, the three latest CLBT EBIT Margin figures stand at 16.15% (Q4 2025), 15.07% (Q3 2025), and 12.73% (Q2 2025).